Our portfolio company hemotune successfully closed a CHF 14 million financing round.
OCCIDENT participated in this Series B2 round led by Belmondo, with continued support from existing investors including VP Venture Partners, HEMEX and Zürcher Kantonalbank, and was joined by EFI Lake Geneva Ventures.
The funds will be used for the clinical development of hemotune’s blood purification platform, HemoSystem. This innovative system can effectively remove large biomolecules directly from patients’ bloodstream. Currently, hemotune is mainly targeting sepsis-induced immunosuppression, but the technology has enormous potential for multiple future applications.
Huge congratulations to Lukas, Carlos, Jean-Claude, Ursina, Stephanie, Sami and the whole team! We look forward to the next exciting steps in the company’s development.
More information in the press release under the following link
More about hemotune
